Affinage

CDK14

Cyclin-dependent kinase 14 · UniProt O94921

Length
469 aa
Mass
53.1 kDa
Annotated
2026-06-09
64 papers in source corpus 26 papers cited in narrative 26 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CDK14 (PFTK1/PFTAIRE1) is a cyclin-dependent serine/threonine kinase that couples cell-cycle progression to Wnt signaling and actin cytoskeletal regulation (PMID:17517622, PMID:19524571, PMID:27821587). Its kinase activity depends on association with a regulatory cyclin: cyclin D3 supports phosphorylation of Rb and is required for CDK14 activity, while siRNA depletion arrests cells in G1 (PMID:17517622), and a yeast two-hybrid-identified partner, cyclin Y, binds via the PFTAIRE motif, enhances kinase activity, and redirects CDK14 to the plasma membrane (PMID:19524571). In a cell-cycle-dependent (G2/M) manner, a quaternary complex of CDK14, cyclin Y, the scaffold Caprin-2, and LRP5/6 drives constitutive LRP5/6 Ser-1490 phosphorylation, priming these Wnt co-receptors (PMID:27821587); CDK14 also phosphorylates LRP6 and GSK3β to stabilize β-catenin and activate canonical Wnt/β-catenin signaling (PMID:24794231, PMID:39447733, PMID:41436436). The cyclin Y/CDK14 pair is autoregulated: CDK14 phosphorylates cyclin Y at Ser-71/73 to create a phospho-degron triggering SCF-Cul1-dependent ubiquitination and degradation, while 14-3-3 proteins enhance the cyclin Y–CDK14 association and CDK7/cyclin H phosphorylates and activates CDK14 (PMID:24794231, PMID:24618387, PMID:31930082). Beyond the cell cycle, CDK14 controls actin dynamics and motility by phosphorylating caldesmon and TAGLN2 (inactivating its actin-binding function) and by activating Rho GTPases through noncanonical Wnt components (PMID:21184254, PMID:21577206, PMID:24824184); it phosphorylates GDP-bound RhoA to regulate axogenesis, and in C. elegans acts kinase-independently via Disheveled to drive a RhoGEF–CDC42–myosin light chain axis promoting axon regeneration (PMID:34429379, PMID:37907898). CDK14 activity promotes tumor progression and therapy resistance via Wnt/β-catenin signaling across breast, esophageal, prostate, glioblastoma, and lung cancer models, and its inhibition is neuroprotective by reducing α-synuclein pathology in synucleinopathy models (PMID:36103813, PMID:38575601, PMID:39702755). CDK14 abundance is post-transcriptionally controlled by METTL1-mediated m7G modification and IGF2BP2 binding to its mRNA, and by RNF213-mediated ubiquitination of the protein (PMID:37599359, PMID:39447733, PMID:40315161).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1998 Medium

    Established the tissue and developmental expression pattern of the CDK14 ortholog, providing the first hint of roles in meiosis and post-mitotic neurons.

    Evidence Northern blot and in situ hybridization in mouse testis, brain, and embryo

    PMID:9547506

    Open questions at the time
    • No molecular function or substrate identified
    • Expression correlation does not establish a mechanism
  2. 2001 Medium

    Localized the human protein to the cytoplasm, beginning the assignment of subcellular context to CDK14 function.

    Evidence GFP fusion expression and fluorescence microscopy in HeLa cells

    PMID:11313143

    Open questions at the time
    • Single overexpression-based localization
    • No functional consequence linked
    • Later work showed cyclin Y can redirect localization to the membrane
  3. 2007 High

    Defined CDK14 as a bona fide cell-cycle kinase by identifying a cyclin partner (cyclin D3), a substrate (Rb), a negative regulator (p21), and a knockdown phenotype (G1 arrest).

    Evidence Reciprocal Co-IP, kinase assays, siRNA knockdown with flow-cytometry cell-cycle analysis in mammalian cells

    PMID:17517622

    Open questions at the time
    • Did not establish which cyclin is the dominant physiological activator
    • No structural basis for activation
  4. 2009 High

    Identified cyclin Y as a CDK14 activating partner that enhances kinase activity and relocalizes the kinase, linking CDK14 to the membrane compartment.

    Evidence Yeast two-hybrid screen, in vivo/in vitro binding, domain mutagenesis, subcellular localization

    PMID:19524571

    Open questions at the time
    • Membrane substrate not yet identified at this stage
    • Relationship between cyclin Y and cyclin D3 activation unresolved
  5. 2014 High

    Revealed a feedback loop and multiple regulatory inputs controlling the cyclin Y/CDK14 module, explaining how its activity is bounded and amplified.

    Evidence MS phospho-site mapping with S71A/S73A mutagenesis and ubiquitination assays (autoregulatory degron); yeast two-hybrid and binding assays (14-3-3); Co-IP and functional readouts (cyclin B, noncanonical Wnt/Rho GTPase) in HCC and other cells

    PMID:24618387 PMID:24794231 PMID:24824184

    Open questions at the time
    • Physiological trigger for autophosphorylation-driven degradation unclear
    • Relative contributions of cyclin Y vs cyclin B in different tissues not resolved
  6. 2014 High

    Connected CDK14 to actin cytoskeletal control by identifying caldesmon and TAGLN2 as substrates whose phosphorylation governs actin binding, motility, and invasion.

    Evidence Phospho-proteomics, site-directed mutagenesis (TAGLN2 S83/S163), epistasis double-knockdown rescue, actin/invasion assays in HCC cells

    PMID:21184254 PMID:21577206

    Open questions at the time
    • Direct kinase-substrate phosphorylation by purified CDK14 not fully established for caldesmon
    • In vivo relevance of these phospho-events untested
  7. 2016 High

    Established the scaffold and cell-cycle context for CDK14's canonical Wnt function: Caprin-2 assembles a CDK14/cyclin Y/LRP5/6 complex driving G2/M LRP5/6 Ser-1490 phosphorylation.

    Evidence Reciprocal Co-IP, siRNA epistasis, cell-cycle-dependent phosphorylation assays

    PMID:27821587

    Open questions at the time
    • Structural arrangement of the quaternary complex unknown
    • How priming is coupled to ligand-induced signaling not detailed here
  8. 2019 High

    Provided a selective covalent chemical tool (FMF-04-159-2) and used it to deconvolute CDK14-specific substrates and confirm a mitotic-progression role.

    Evidence Covalent inhibitor development, SAR, washout phospho-proteomics, cell-cycle analysis

    PMID:30930164 PMID:31175010

    Open questions at the time
    • Putative substrates from phospho-proteomics not individually validated
    • TAIRE-family cross-reactivity bounds interpretation
  9. 2021 High

    Uncovered a kinase-independent mode of CDK14 action in neurons, showing it can drive a Disheveled–RhoGEF–CDC42–MLC axis to promote axon regeneration.

    Evidence C. elegans genetic epistasis, binding studies, GEF activity assays, phospho-mimetic rescue in motor neurons

    PMID:34429379

    Open questions at the time
    • Whether the kinase-independent mechanism operates in mammals not shown
    • Structural basis of CDK14–Disheveled binding undefined
  10. 2022 High

    Connected CDK14 activity to cancer dependency, demonstrating that genetic or pharmacological inhibition suppresses Wnt-driven mammary tumor and TNBC progression, and that CDK7 activates CDK14 to phosphorylate Rb and confer chemoresistance.

    Evidence Knockdown plus FMF-04-159-2, MMTV-Wnt-1 in vivo model, colony assays (breast); Co-IP, co-localization, truncation analysis, colony/cisplatin assays in ESCC

    PMID:31930082 PMID:36103813

    Open questions at the time
    • Direct in vivo demonstration of CDK7-CDK14-Rb axis limited to one cancer type
    • Therapeutic window of CDK14 inhibition not defined
  11. 2023 High

    Identified RhoA as a direct CDK14 substrate in axogenesis and showed cross-species (Drosophila, mouse KO) requirement for CDK14 in axon development.

    Evidence Drosophila loss-of-function, PFTK1 knockout mice, RhoA phosphorylation assays in primary neurons

    PMID:37907898

    Open questions at the time
    • Phospho-site on RhoA and structural consequence of phosphorylation not detailed
    • Reconciliation with kinase-independent regeneration mechanism open
  12. 2023 High

    Revealed post-transcriptional control of CDK14 abundance via METTL1-mediated internal m7G modification that stabilizes its mRNA to promote castration-resistant prostate cancer.

    Evidence m7G AlkAniline-Seq, mRNA degradation assays, ChIP-qPCR, Co-IP, luciferase reporter

    PMID:37599359

    Open questions at the time
    • Whether m7G control operates outside CRPC unknown
    • Downstream CDK14 substrates in this context not mapped
  13. 2024 High

    Demonstrated CDK14 as a therapeutic target in synucleinopathy, with loss or inhibition reducing α-synuclein pathology, and extended Wnt regulation to osteogenesis under IGF2BP2-mediated mRNA stabilization.

    Evidence Cdk14 KO PFF mouse model and pharmacological inhibition across human/rat neurons (α-Syn); Co-IP, siRNA, inhibitor, and LRP6/GSK3β/β-catenin readouts in osteogenesis

    PMID:38575601 PMID:39447733

    Open questions at the time
    • Molecular substrate linking CDK14 to α-Syn levels not identified
    • Whether α-Syn effect is Wnt-dependent unknown
  14. 2024 Medium

    Showed epigenetic and Wnt-mediated control of drug resistance: gefitinib derepresses CDK14 via DNMT3B-dependent promoter demethylation, and CDK14-LRP6-Wnt signaling attenuates apoptosis.

    Evidence Promoter methylation analysis, DNMT3B manipulation, Co-IP, in vitro/in vivo pharmacological inhibition in NSCLC

    PMID:39702755

    Open questions at the time
    • Single-lab mechanism
    • Generality of methylation control across CDK14-driven cancers untested
  15. 2025 Medium

    Broadened CDK14's physiological roles to tissue repair and inflammation: it is required for endothelial/epithelial proliferation and lung repair via a STAT1/IFN axis, while RNF213-mediated ubiquitination restrains CDK14-Pdgfrβ signaling in macrophage polarization, and IRX3-driven transcription couples CDK14 to β-catenin stabilization in glioblastoma.

    Evidence Cdk14 KO mice with lung injury models and RNA-seq (STAT1/IFN); macrophage polarization assays with RNF213 manipulation; ChIP and β-catenin ubiquitination assays in GBM

    PMID:39827158 PMID:40315161 PMID:41436436

    Open questions at the time
    • Direct CDK14 substrates in the STAT1/IFN and Pdgfrβ axes not defined
    • Single-lab mechanisms for RNF213 and IRX3 links

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how CDK14 partitions between its distinct cyclin partners (D3, Y, B) and between kinase-dependent and kinase-independent modes across tissues, and which substrate connects it to α-synuclein homeostasis.
  • No structural model of CDK14-cyclin or CDK14-substrate complexes in the corpus
  • Substrate linking CDK14 to α-Syn levels unidentified
  • Tissue-specific cyclin selection rules unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0016740 transferase activity 4 GO:0140110 transcription regulator activity 2
Localization
GO:0005886 plasma membrane 2 GO:0005634 nucleus 1 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 6 R-HSA-1640170 Cell Cycle 4 R-HSA-1266738 Developmental Biology 2
Partners
14-3-3CAPRIN-2CCND3CCNYCDK7DVL2LRP6RHOA
Complex memberships
CDK14/cyclin D3/p21CDK14/cyclin YCDK14/cyclin Y/Caprin-2/LRP5/6 quaternary complexCDK7/cyclin H (CAK)

Evidence

Reading pass · 26 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 Human PFTAIRE1 (CDK14) protein is localized to the cytoplasm when expressed as a GFP fusion in HeLa cells, as determined by fluorescence microscopy. GFP fusion protein expression and fluorescence microscopy in HeLa cells Gene Medium 11313143
1998 Mouse Pftaire-1 (CDK14 ortholog) is expressed in late pachytene spermatocytes in the testis and in post-mitotic neuronal cells in the brain and embryo, suggesting roles in meiosis and neuron differentiation, as established by in situ hybridization. Northern blot and in situ hybridization in mouse tissues Molecular reproduction and development Medium 9547506
2007 Human PFTK1 (CDK14) specifically interacts with cyclin D3 (CCND3) and forms a ternary complex with p21(Cip1); CCND3 is required for PFTK1 kinase activity, which is negatively regulated by p21(Cip1); Rb is a downstream phosphorylation substrate of the PFTK1/CCND3 complex; siRNA knockdown of PFTK1 causes G1 cell cycle arrest. Co-immunoprecipitation, siRNA knockdown, cell cycle analysis (flow cytometry), kinase assays in mammalian cells Proceedings of the National Academy of Sciences of the United States of America High 17517622
2009 Cyclin Y (CCNY) is a novel interacting partner of PFTK1 (CDK14) identified by yeast two-hybrid screen; the cyclin box of CCNY and the PFTAIRE motif of PFTK1 are both required for the interaction; binding of CCNY to PFTK1 enhances PFTK1 kinase activity and changes its intracellular localization; CCNY is enriched at the plasma membrane via an N-terminal myristoylation signal. Yeast two-hybrid screen, in vivo and in vitro binding assays, Northern blot, subcellular localization studies FEBS letters High 19524571
2010 Caldesmon (CaD) is a downstream phosphorylation substrate of PFTK1 (CDK14); PFTK1 knockdown reduces CaD phosphorylation and causes dissociation of CaD from F-actin fibers, loss of actin stress fibers, and altered CaD subcellular localization in hepatocellular carcinoma cells. siRNA knockdown, immunofluorescence, co-localization analysis, phosphorylation assays in HCC cells Molecular and cellular biochemistry Medium 21184254
2011 PFTK1 (CDK14) phosphorylates TAGLN2 (transgelin2) at residues S83 and S163, inactivating its actin-binding function; in PFTK1-suppressed cells, unphosphorylated TAGLN2 exhibits strong actin-binding ability that inhibits actin cytoskeleton dynamics and cell motility; knockdown of TAGLN2 in PFTK1-suppressed cells rescues cell invasion and motility and restores actin polymerization. β-actin (ACTB) tyrosine phosphorylation is also affected by PFTK1. 2D-PAGE mass spectrometry, siRNA knockdown, site-directed mutagenesis of TAGLN2, cell invasion/motility assays, actin polymerization assays Oncogene High 21577206
2014 PFTK1 (CDK14) forms a direct complex with cyclin Y (CCNY) in HCC cells; this complex upregulates key components of noncanonical Wnt signaling (Dvl2 and Naked1) and activates Rho GTPases, leading to actin polymerization. Co-immunoprecipitation, exogenous expression, Rho GTPase activation assays, actin polymerization assays in HCC cells Biochemical and biophysical research communications Medium 24824184
2014 CDK14 phosphorylates cyclin Y (CCNY) at Ser-71 and Ser-73, creating a phospho-degron that triggers CCNY ubiquitination by an SCF-Cul1 complex and its proteasomal degradation; mutation of these serines to alanine stabilizes CCNY and enhances CCNY/CDK14 activity on LRP6 phosphorylation, representing autoregulation of the cyclin Y/CDK14 pair. In vivo and in vitro phosphorylation mapping by mass spectrometry, Cul1 inactivation, site-directed mutagenesis (S71A/S73A), ubiquitination assays, LRP6 phosphorylation assays FEBS letters High 24794231
2014 14-3-3 proteins (ε, β, η, τ isoforms) interact with cyclin Y (CCNY) via Ser-100 and Ser-326 residues, and this binding significantly enhances the association between CCNY and CDK14. Yeast two-hybrid screen, in vitro and in vivo binding assays, site-directed mutagenesis Acta biochimica et biophysica Sinica Medium 24618387
2015 CDK14 interacts with cyclin Y in spinal cord injury (SCI) rat model; CDK14 expression increases and peaks at 3 days post-SCI; CDK14 co-localizes with cyclin Y and with PCNA in astrocytes/glial cells, suggesting a role in reactive gliosis. Western blot, immunohistochemistry, double immunofluorescence, Co-immunoprecipitation in rat SCI model Journal of molecular neuroscience : MN Medium 26315607
2015 PFTK1 (CDK14) knockdown in breast cancer cells attenuates Wnt/β-catenin signaling by reducing DVL2 levels and inhibiting β-catenin transcriptional targets (cyclin D1, MMP9, HEF1); PFTK1 interacts with cyclin B, and this complex increases DVL2 levels. Co-immunoprecipitation (cyclin B interaction), siRNA knockdown, Western blot, proliferation/migration/invasion assays in breast cancer cells Medical oncology Medium 26033031
2015 PFTK1 (CDK14) knockdown in oligodendrocyte progenitor cell-derived OLN-93 cells promotes oligodendrocyte differentiation (increased CNPase, MOG, CGT, MBP markers); this effect is mediated through activation of the PI3K/AKT pathway but not the MAPK/ERK pathway, as AKT-specific inhibitor abrogates the differentiation-promoting effect of PFTK1 silencing. siRNA knockdown, qPCR, Western blot, AKT inhibitor epistasis in OLN-93 cells Journal of molecular neuroscience : MN Medium 25355490
2016 Caprin-2 positively regulates constitutive LRP5/6 Ser-1490 phosphorylation in a cell cycle-dependent manner (G2/M) by forming a quaternary complex with CDK14, Cyclin Y, and LRP5/6; Caprin-2 knockdown disrupts the CDK14–Cyclin Y interaction and the CDK14/Cyclin Y–LRP6 interaction. Co-immunoprecipitation, siRNA knockdown, cell cycle-dependent phosphorylation assays The Journal of biological chemistry High 27821587
2019 FMF-04-159-2 is a potent covalent CDK14 inhibitor with TAIRE kinase-biased selectivity; covalent CDK14 inhibition affects cell-cycle regulation, particularly mitotic progression; phospho-proteomics under washout conditions identified putative CDK14-specific substrates. Covalent inhibitor development, phospho-proteomics, cell-cycle analysis with washout conditions Cell chemical biology High 30930164
2019 Synthesis and SAR of covalent 4-amino-1H-pyrazole CDK14 inhibitors culminated in FMF-04-159-2, a potent, covalent CDK14 inhibitor with TAIRE kinase-biased selectivity profile. Medicinal chemistry synthesis, structure-activity relationship analysis, biochemical kinase selectivity profiling Bioorganic & medicinal chemistry letters Medium 31175010
2021 In C. elegans, CDK-14 (mammalian CDK14 homolog) promotes axon regeneration via noncanonical Wnt signaling in a kinase-independent manner: CDK-14 binds MIG-5/Disheveled and activates EPHX-1 (ephexin RhoGEF), which activates CDC-42, inhibiting myosin phosphatase and maintaining MLC-4 phosphorylation. EGL-20/Wnt and MIG-1/Frizzled are required for efficient axon regeneration. Genetic epistasis (C. elegans), binding studies, GEF activity assays, phospho-mimetic rescue experiments in motor neurons The Journal of neuroscience High 34429379
2022 CDK14 knockdown or pharmacological inhibition (FMF-04-159-2) reduces mammary basal cell colony-formation and regeneration capacity, inhibits MMTV-Wnt-1 mammary tumor progression, and suppresses TNBC progression and metastasis by attenuating Wnt/β-catenin signaling. Genetic knockdown, pharmacological inhibition (FMF-04-159-2), in vivo MMTV-Wnt-1 mouse model, in vitro colony-formation assays, Wnt signaling readouts Cell reports High 36103813
2022 CDK7/cyclin H (CAK complex) physically interacts with CDK14 in the cell nucleus and increases CDK14 phosphorylation; this activates CDK14 to phosphorylate Rb, inhibiting Rb function; overexpression of CDK7 with CDK14 strengthens colony formation and cisplatin resistance in ESCC cells. Co-immunoprecipitation, immunofluorescence co-localization, truncation mutant analysis, colony formation assays in ESCC cells Annals of translational medicine Medium 31930082
2023 In Drosophila, Eip63E (CDK14 ortholog) regulates axogenesis; PFTK1 knockout mice show increased axonal outgrowth; PFTK1 phosphorylates GDP-bound inactive RhoA and this phosphorylation is required for RhoA activity, establishing RhoA as a CDK14 substrate mediating axon development. Drosophila genetic loss-of-function, PFTK1 knockout mouse model, RhoA phosphorylation assays in primary neuronal cultures, functional interaction studies BMC biology High 37907898
2023 METTL1 adds internal m7G modifications to CDK14 mRNA, enhancing its stability and thereby promoting CRPC progression; the P300/SP1 complex binds the METTL1 promoter via SP1, mediating METTL1 transcriptional upregulation in CRPC. ChIP-qPCR, Co-IP, luciferase reporter assay, m7G AlkAniline-Seq, mRNA degradation assays, transcriptome sequencing Journal of experimental & clinical cancer research High 37599359
2024 CDK14 loss in the preformed fibrils (PFF) mouse model of Parkinson's disease mitigates grip strength deficits and reduces pS129 α-synuclein pathology in the cortex; Cdk14 depletion in primary neurons protects against propagation of toxic α-Syn species; pharmacological CDK14 inhibition (FMF-04-159-2) decreases total and pathologically aggregated α-Syn in human neurons, PFF-challenged rat neurons, and α-Syn-humanized mouse brains. Genetic Cdk14 knockout in PFF mouse model, primary neuron depletion assays, pharmacological inhibition in multiple model systems, pS129 α-Syn immunostaining Cell death & disease High 38575601
2024 IGF2BP2 interacts with CDK14 mRNA, stabilizing it by inhibiting its degradation; CDK14 facilitates LRP6 and GSK3β phosphorylation, thereby regulating β-catenin levels and Wnt/β-catenin signaling during osteogenic differentiation. Co-IP (IGF2BP2-CDK14 mRNA interaction), siRNA knockdown, CDK14 inhibitor (FMF-04-159-2), Western blot for LRP6/GSK3β/β-catenin phosphorylation, osteogenesis assays Life sciences Medium 39447733
2024 Gefitinib suppresses PFTK1 (CDK14) promoter methylation in a DNMT3B-dependent manner, upregulating CDK14 expression; CDK14 interacts with LRP6 and activates Wnt/β-catenin signaling to attenuate gefitinib-induced apoptosis and confer gefitinib resistance in NSCLC; FMF-04-159-2 reverses CDK14-mediated gefitinib resistance in vitro and in vivo. Promoter methylation analysis, DNMT3B manipulation, Co-IP (CDK14-LRP6), gain/loss-of-function assays, pharmacological inhibition in vitro and in vivo Communications biology Medium 39702755
2025 Genetic ablation of Cdk14 in mice impairs pulmonary vascular endothelial and alveolar epithelial cell proliferation, causes G2/M cell cycle arrest, and increases mortality and severity of bleomycin- or LPS-induced lung injury; RNA-seq reveals CDK14 knockdown controls STAT1 expression and interferon-signaling-associated genes; CDK14 disruption interferes with IFN-γ-induced lung repair. Cdk14 knockout mouse model, CDK14 covalent inhibitor FMF-04-159-2, RNA-seq, cell cycle analysis, in vivo lung injury models Cell death discovery High 39827158
2025 RNF213 ubiquitinates CDK14, inhibiting the CDK14-Pdgfrβ signaling pathway; maltol upregulates RNF213, thereby suppressing CDK14-Pdgfrβ signaling, M1 macrophage polarization, and NF-κB phosphorylation. In vitro and in vivo macrophage polarization assays, Western blot for CDK14-Pdgfrβ pathway, RNF213 overexpression/knockdown Journal of agricultural and food chemistry Medium 40315161
2025 IRX3 promotes CDK14 transcription by binding to its promoter (ChIP-confirmed); CDK14 then stabilizes β-catenin by restraining its ubiquitination and degradation, activating canonical Wnt/β-catenin signaling; LRP6 is identified as a crucial regulatory factor in IRX3-CDK14-mediated β-catenin stabilization in glioblastoma. ChIP assay, luciferase reporter assay, gain/loss-of-function in GBM cells, Western blot for β-catenin ubiquitination/stability Cell death & disease Medium 41436436

Source papers

Stage 0 corpus · 64 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer. Journal of cellular biochemistry 78 30474270
2011 A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene 78 21577206
2017 miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14. Cell death & disease 77 29022909
2009 Cyclin Y, a novel membrane-associated cyclin, interacts with PFTK1. FEBS letters 77 19524571
2018 Long non-coding RNA SNHG15 promotes CDK14 expression via miR-486 to accelerate non-small cell lung cancer cells progression and metastasis. Journal of cellular physiology 71 29630731
2018 The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1. Journal of experimental & clinical cancer research : CR 65 30185212
2007 Functional characterization of human PFTK1 as a cyclin-dependent kinase. Proceedings of the National Academy of Sciences of the United States of America 58 17517622
2019 The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis. Cancer biology & therapy 55 30915884
2018 Long noncoding RNA OIP5-AS1 accelerates CDK14 expression to promote osteosarcoma tumorigenesis via targeting miR-223. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 53 30119217
2023 P300/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC. Journal of experimental & clinical cancer research : CR 51 37599359
2017 miR-455 inhibits breast cancer cell proliferation through targeting CDK14. European journal of pharmacology 45 28300591
2014 PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma. Biochemical and biophysical research communications 44 24824184
2015 PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion. PloS one 42 26488471
2001 Identification and cellular localization of human PFTAIRE1. Gene 41 11313143
2021 Hypoxia associated lncRNA HYPAL promotes proliferation of gastric cancer as ceRNA by sponging miR-431-5p to upregulate CDK14. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 40 34247316
2018 MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 38 30557834
2018 Knockdown of NEAT1 repressed the malignant progression of glioma through sponging miR-107 and inhibiting CDK14. Journal of cellular physiology 37 30480816
1998 The identification and characterization of expression of Pftaire-1, a novel Cdk family member, suggest its function in the mouse testis and nervous system. Molecular reproduction and development 35 9547506
2018 Long noncoding RNA LINC00858 promotes osteosarcoma through regulating miR-139-CDK14 axis. Biochemical and biophysical research communications 32 29944887
2012 Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. British journal of cancer 29 22333595
2019 CDK14 involvement in proliferation migration and invasion of esophageal cancer. Annals of translational medicine 28 31930082
2015 Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer. Medical oncology (Northwood, London, England) 28 26033031
2018 LINC00707 contributes to hepatocellular carcinoma progression via sponging miR-206 to increase CDK14. Journal of cellular physiology 26 30488589
2019 Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. Cell chemical biology 23 30930164
2016 PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer. International journal of biological macromolecules 23 26772918
2022 CDK14 inhibition reduces mammary stem cell activity and suppresses triple negative breast cancer progression. Cell reports 22 36103813
2016 Activation/Proliferation-associated Protein 2 (Caprin-2) Positively Regulates CDK14/Cyclin Y-mediated Lipoprotein Receptor-related Protein 5 and 6 (LRP5/6) Constitutive Phosphorylation. The Journal of biological chemistry 21 27821587
2018 TCF3-activated LINC00152 exerts oncogenic role in osteosarcoma through regulating miR-1182/CDK14 axis. Pathology, research and practice 20 30600185
2021 Hsa_circRNA_102229 facilitates the progression of triple-negative breast cancer via regulating the miR-152-3p/PFTK1 pathway. The journal of gene medicine 19 34031947
2016 Knockdown of PFTAIRE Protein Kinase 1 (PFTK1) Inhibits Proliferation, Invasion, and EMT in Colon Cancer Cells. Oncology research 18 27458094
2022 CircRNA_0078767 promotes osteosarcoma progression by increasing CDK14 expression through sponging microRNA-330-3p. Chemico-biological interactions 16 35307379
2015 Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer. International journal of clinical and experimental pathology 16 26823712
2015 Knockdown of PFTK1 Inhibits the Migration of Glioma Cells. Journal of molecular neuroscience : MN 15 26234562
2010 Phosphorylation of Caldesmon by PFTAIRE1 kinase promotes actin binding and formation of stress fibers. Molecular and cellular biochemistry 15 21184254
2018 MiR-431 inhibits cell proliferation and induces cell apoptosis by targeting CDK14 in pancreatic cancer. European review for medical and pharmacological sciences 14 30058687
2020 Upregulation of miR-1825 inhibits the progression of glioblastoma by suppressing CDK14 though Wnt/β-catenin signaling pathway. World journal of surgical oncology 13 32605563
2015 CDK14 Contributes to Reactive Gliosis via Interaction with Cyclin Y in Rat Model of Spinal Cord Injury. Journal of molecular neuroscience : MN 13 26315607
2014 Phosphorylation of cyclin Y by CDK14 induces its ubiquitination and degradation. FEBS letters 12 24794231
2021 LncRNA NORAD accelerates the progression of non-small cell lung cancer via targeting miRNA-455/CDK14 axis. Minerva medica 11 33764714
2014 14-3-3 Binding to Cyclin Y contributes to cyclin Y/CDK14 association. Acta biochimica et biophysica Sinica 11 24618387
2021 CDK14 Promotes Axon Regeneration by Regulating the Noncanonical Wnt Signaling Pathway in a Kinase-Independent Manner. The Journal of neuroscience : the official journal of the Society for Neuroscience 10 34429379
2020 Long noncoding RNAs SET-binding factor 2-antisense RNA1 promotes cell growth through targeting miR-431-5p/CDK14 axis in human papillary thyroid cancer. The Kaohsiung journal of medical sciences 9 32602632
2014 Serine/threonine-protein kinase PFTK1 modulates oligodendrocyte differentiation via PI3K/AKT pathway. Journal of molecular neuroscience : MN 9 25355490
2022 Silencing of circ-CDK14 suppresses osteosarcoma progression through the miR-198/E2F2 axis. Experimental cell research 8 35218724
2016 Knockdown of PFTK1 Expression by RNAi Inhibits the Proliferation and Invasion of Human Non-Small Lung Adenocarcinoma Cells. Oncology research 8 27458099
2015 CDK14 expression is down-regulated by cigarette smoke in vivo and in vitro. Toxicology letters 8 25680692
2021 CDK14/β-catenin/TCF4/miR-26b positive feedback regulation modulating pancreatic cancer cell phenotypes in vitro and tumor growth in mice model in vivo. The journal of gene medicine 7 33871149
2020 The anti-tumor effect of miR-539-3p on colon cancer via regulating cell viability, motility, and nude mouse tumorigenicity with CDK14 inhibition. Journal of gastrointestinal oncology 7 33209486
2025 CDK14 regulates the development and repair of lung. Cell death discovery 5 39827158
2024 Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy. Cell death & disease 5 38575601
2021 Depletion of circRNA circ_CDK14 inhibits osteosarcoma progression by regulating the miR-520a-3p/GAB1 axis. Neoplasma 5 34348465
2021 Amygdala DCX and blood Cdk14 are implicated as cross-species indicators of individual differences in fear, extinction, and resilience to trauma exposure. Molecular psychiatry 5 34728797
2025 Mechanistic Insights into Maltol-Mediated Reversal of Postmenopausal Osteoporosis via Regulation of CDK14 Ubiquitination in Macrophages. Journal of agricultural and food chemistry 4 40315161
2024 CDK14 is regulated by IGF2BP2 and involved in osteogenic differentiation via Wnt/β-catenin signaling pathway in vitro. Life sciences 3 39447733
2024 Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells. Communications biology 3 39702755
2023 miR-1-3p Inhibits Osteosarcoma Cell Proliferation and Cell Cycle Progression While Promoting Cell Apoptosis by Targeting CDK14 to Inactivate Wnt/Beta-Catenin Signaling. Molecular biotechnology 3 37420040
2020 Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer. OncoTargets and therapy 2 33061417
2019 Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14. Bioorganic & medicinal chemistry letters 2 31175010
2025 5-Hydroxytryptamine promotes non-small cell lung cancer metastasis via the SNRPG/WT1/CDK14 Axis. Molecular biomedicine 1 41016985
2025 IRX3-CDK14 axis promotes glioblastoma progression by regulating LRP6-mediated canonical Wnt/β-catenin pathway. Cell death & disease 1 41436436
2023 Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing. Cancer biology & therapy 1 37906510
2023 PFTK1 kinase regulates axogenesis during development via RhoA activation. BMC biology 1 37907898
2026 CDK14 is a critical regulator of haematopoietic stem and progenitor cell maintenance and post-transplantation proliferation. The FEBS journal 0 42080702
2025 RETRACTION: Long Non-Coding RNA SNHG15 Promotes CDK14 Expression via miR-486 to Accelerate Non-Small Cell Lung Cancer Cells Progression and Metastasis. Journal of cellular physiology 0 40696975

Missed literature

Know a paper Affinage missed for CDK14? Flag it for the maintainers and the community.

No submissions yet.